Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InflammaSTOP: Ruxolitinib + Pembrolizumab in HNSCC with High NLR
NCT07840456Phase 2Not yet recruiting
- Sponsor
- University Hospital Basel
- Start
- Nov 2026
- Primary completion
- Feb 2029
- Countries
- 2
01
Overview
A Phase 2 trial of ruxolitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University Hospital Basel. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07840456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840456.